Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Gaush Meditech Ltd
高视医疗科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2407)

PROFIT WARNING
SUPPLEMENTAL ANNOUNCEMENT

This announcement is made by Gaush Meditech Ltd (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to the Inside Information Provisions (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09(2)(a) of the Listing Rules.

Reference is made to the profit warning announcement of the Company dated July 23, 2026 (the "**Profit Warning Announcement**"). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Profit Warning Announcement.

The Board wishes to further inform the Shareholders and potential investors that based on a preliminary review of the unaudited consolidated management accounts of the Group for the six months ended June 30, 2026 and the information currently available to the Company immediately preceding the publication of this announcement, it is expected that the Group will record a revenue of approximately RMB583.2 million to RMB607.0 million for the six months ended June 30, 2026 for the reasons as set out in the Profit Warning Announcement, as compared to the revenue of approximately RMB653.1 million for the six months ended June 30, 2025, representing a decrease by approximately 7.1% to 10.7%.

Save for the supplementary information disclosed above, all other information and content set out in the Profit Warning Announcement remain unchanged. This announcement is supplemental to and should be read in conjunction with the Profit Warning Announcement.

As of the date of this announcement, the Company is still in the process of finalizing the consolidated interim results of the Group for the six months ended June 30, 2026. The information contained in this announcement is based on a preliminary review of the unaudited consolidated management accounts of the Group and information currently available to the Board for the six months ended June 30, 2026, which has not been reviewed or audited by the auditors of the Company or reviewed by the audit committee of the Board. Shareholders and potential investors of the Company are advised to read carefully the interim results announcement of the Company for the six months ended June 30, 2026, which is expected to be published by the end of August 2026.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Gaush Meditech Ltd
Mr. Gao Tieta
Chairman and Executive Director

Hong Kong, August 3, 2026

As of the date of this announcement, the Board comprises Mr. Gao Tieta as Chairman and executive Director, Mr. Liu Xinwei, Mr. Zhao Xinli, Mr. Zhang Jianjun and Ms. Li Wenqi as executive Directors, Dr. David Guowei Wang as non-executive Director, and Ms. Cheng Juan, Mr. Yubing Li and Ms. Qiu Xiaoling as independent non-executive Directors.